First-in-Human Treatment of Severe Tricuspid Regurgitation Using a Novel Cross-Caval Heterotopic Device

Antonio Sisinni; Rodrigo Estévez-Loureiro; Berenice Caneiro-Queija; Manuel Barreiro-Pérez; Jose A Baz; Pablo Pazos; Rocio Gonzalez-Ferreiro; Andrés Iñiguez-Romo

doi:10.1016/j.jaccas.2023.102103

First-in-Human Treatment of Severe Tricuspid Regurgitation Using a Novel Cross-Caval Heterotopic Device

JACC Case Rep. 2023 Nov 2:28:102103. doi: 10.1016/j.jaccas.2023.102103. eCollection 2023 Dec 20.

Authors

Antonio Sisinni^{1

2}, Rodrigo Estévez-Loureiro^{1

2}, Berenice Caneiro-Queija^{1

2}, Manuel Barreiro-Pérez^{1

2}, Jose A Baz^{1

2}, Pablo Pazos^{1

2}, Rocio Gonzalez-Ferreiro^{1

2}, Andrés Iñiguez-Romo^{1

2}

Affiliations

¹ Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain.
² Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Galicia Sur Health Research Institute (IIS Galicia Sur), Servizo Galego de Saude, University of Vigo, Vigo, Spain.

Abstract

A 79-year-old woman, previously surgically treated for mitral and aortic valve replacement, experienced recurrent torrential tricuspid regurgitation after 2 transcatheter edge-to-edge repair procedures. Heart team assessment deemed the patient high risk for redo surgery and excluded transcatheter edge-to-edge repair and orthotopic replacement. The patient was then scheduled for a novel cross-caval device implantation.

Keywords: CAVI; caval valve implantation; transcatheter therapies; tricuspid regurgitation.